Enliven Therapeutics ELVN Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's quick ratio?
- Enliven Therapeutics (ELVN) reported quick ratio of 40.3× in Q1 2026.
- How has Enliven Therapeutics's quick ratio changed year-over-year?
- Enliven Therapeutics's quick ratio increased by 91.4% year-over-year, from 21.1× to 40.3×.
- What is the long-term trend for Enliven Therapeutics's quick ratio?
- Over 5 years (2020 to 2025), Enliven Therapeutics's quick ratio has grown at a 14.6% compound annual growth rate (CAGR), from 14.5× to 28.7×.
- What does quick ratio mean?
- Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.